Some big and potentially practice changing articles this month. (I tend to read ridiculous articles in my free time, which I have had very little of, and so there are no intubation in outer space or highly philosophical papers about the language this month. Don’t worry, there is still a […]
Andexanet Alfa
4 posts
We have previously discussed the many pharmaceutical advertisements published by the New England Journal of Medicine, thinly disguised as science, such as the original open label uncontrolled look at andexanet alfa. (Connolly 2019) At that point, I concluded that andexanet alfa should clearly not be used (although our pharmacies didn’t […]
In the first edition of the research roundup for 2019 we are going to cover pediatric head injury, oral antibiotics for complicated orthopedic infections, shaving eyebrows, bad science in the New England Journal of Medicine, a decision rule for opioid overdose, shark bites, heparin for ACS, cardiac monitoring in syncope, […]
Last year, the FDA granted andexanet alfa an accelerated approval as a reversal agent for factor Xa inhibitors, but based that decision on a complete lack of useable science. This decision is almost identical to the approval of idarucizumab, a debacle I have discussed previously. (At that time, I was […]